Learn how Series 26 tests net capital, SIPC, fidelity bonds, new product due diligence, product rollout controls, annual reports, proxy notices, CMA triggers, business changes, and ongoing product oversight.
Series 26 closes its compliance-process function with firm-level oversight. The principal must know when product decisions, financial-responsibility issues, corporate-action delivery, or business-line changes require broader review before the firm acts. A new packaged product is not just a sales opportunity. It can change training, disclosures, supervision, capital assumptions, customer communications, and membership obligations.
The exam rewards controlled expansion. If the firm wants to add a product, alter a business line, or respond to a capital or customer-protection concern, the principal should ask whether the firm’s registrations, procedures, controls, training, disclosures, and reporting obligations are ready.
| Issue | Principal question | Strong Series 26 response |
|---|---|---|
| Net capital or aggregate indebtedness | Is the firm approaching an early warning or deficiency trigger? | escalate, curtail activity if needed, and document the response |
| SIPC information | Are customers receiving accurate SIPC information without confusing it with deposit insurance? | correct disclosures and train personnel |
| Fidelity bond | Does the firm maintain required operational-risk coverage? | verify coverage and remediation for gaps |
| New product proposal | Has due diligence defined risks, target customers, conflicts, and controls? | update WSPs, disclosures, training, surveillance, and approvals before launch |
| New business line | Does the change affect membership, registration, capital, or supervision? | evaluate CMA or notice issues before rollout |
| Annual reports or proxy notices | Are delivery and operational controls reliable? | supervise delivery, records, and exception handling |
Product due diligence should identify product structure, fees, liquidity, surrender charges, riders, target customer, risk profile, compensation conflicts, disclosure requirements, sales limits, training needs, and surveillance triggers. For mutual funds and variable products, product approval should also address share-class issues, breakpoint controls, replacement risks, rider explanations, and ongoing product monitoring.
Series 26 usually prefers the answer that pauses a rollout until controls are complete. A representative’s belief that a product will be popular does not substitute for product review, WSP updates, training, and post-launch exception reporting.
The principal does not need to perform every financial calculation, but Series 26 expects recognition of capital and customer-protection warning signs. Net capital, aggregate indebtedness, business curtailment, regulatory notification, fidelity bonds, SIPC disclosures, and firm funding issues can all require escalation outside the immediate sales desk.
Continuance in membership application concepts also matter. A major business change can require internal review and potentially regulatory approval before implementation. The exam point is timing: the firm should evaluate regulatory consequences before the business change is treated as final.
Approval is not the end of supervision. The firm should monitor exceptions, complaints, sales concentration, compensation effects, customer profiles, disclosures, and training outcomes after a product or business line is introduced. If metrics show a pattern, the principal should update controls or restrict activity rather than assuming the original approval remains sufficient.
A firm wants to add a new variable product with complex riders and different compensation than its current product menu. What is the strongest Series 26 response?
A. Approve sales immediately if representatives believe customers will like the riders B. Complete product due diligence, define target customers and conflicts, update WSPs and training, and confirm whether any business or membership implications exist before rollout C. Allow the product only for high-net-worth customers without additional review D. Skip training if the product sponsor provides marketing materials
Answer: B. Series 26 expects new product supervision to occur before launch, with due diligence, procedure updates, conflict review, and documented controls.